CSL (ASX: CSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CSL Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CSL (ASX: CSL)
Latest News
⏸️ Investing
How well do you really know CSL Limited?
⏸️ Investing
2 stocks set to smash the ASX: CSL Limited and Amcor Limited
⏸️ Investing
Did you miss the major news from the ASX this week?
⏸️ Investing
S&P/ASX 200 surges as CSL Limited lifts: What you need to know
⏸️ Investing
Morning market movers: 8 stocks to watch
⏸️ Investing
Why these 4 ASX healthcare stocks are falling today
⏸️ Investing
Why it's not too late to buy CSL Limited shares
⏸️ Investing
2 stocks to buy and 3 to sell
⏸️ Investing
The bull case for CSL Limited
⏸️ Investing
The Race to $100: A new contender
⏸️ Investing
2 stocks set to beat the ASX: CSL Limited and Macquarie Group Ltd
⏸️ Investing
3 stocks to benefit from a falling Australian dollar
Frequently Asked Questions
-
CSL was listed on the ASX in June 1994.
-
CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.
Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.
-
CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.
-
CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents.
CSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CSL
CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.
CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.
CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).
The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.
